Aardvark Therapeutics FDA Hold Lifted, Cash $60.3M Through 2027

Aardvark Therapeutics (Nasdaq: AARD) said on 13 November 2026 that the U.S. Food and Drug Administration lifted its clinical hold on ARD-101, the company's experimental treatment for hyperphagia in Prader-Willi Syndrome, in October 2026. The company ended the third quarter with $60.3 million in cash, cash equivalents and short-term investments, down from $73.9 million at 30 June 2026, and said that balance funds projected operations through 2027. Third-quarter net loss widened to $19.2 million from $16.3 million a year earlier.

Context — why the FDA hold decision matters now

The FDA placed the hold on Aardvark's Investigational New Drug application for ARD-101, and the October 2026 removal clears the path for the company to restart clinical work in Prader-Willi Syndrome. Aardvark said it has requested a meeting with the FDA, now scheduled for the first quarter of 2027, to discuss its proposed clinical development plan for ARD-101. The company expects to resume PWS clinical activities in 2027, subject to alignment with the agency.

As a condition of lifting the hold, the FDA required an electrocardiogram study in healthy volunteers and an in vitro cardiac sodium channel study. Aardvark reported that no prolongation of the QRS interval or the QT interval appeared at ARD-101 doses of 200 mg or 400 mg twice daily. The FDA agreed Aardvark may run an open-label trial at 200 mg BID in PWS patients.

The company's lead program sits in a niche indication with no approved hunger-specific therapy that Aardvark names in the report. The clinical hold had frozen enrollment and dosing, which is why the October 2026 removal is the single event that resets the timeline. The prior-quarter cash figure of $73.9 million gives the burn baseline against which the latest $60.3 million is measured.

Aardvark is a clinical-stage company. It has no approved product and no product revenue, so its valuation rests on pipeline progress and on the cash runway it can protect. The report does not disclose the terms of any financing, partnership or licensing arrangement.

Data — what the numbers show

The financial picture is a widening loss funded by a shrinking cash pile. Third-quarter research and development expense rose to $15.7 million from $13.7 million a year earlier, a $1.9 million increase that Aardvark attributed mainly to the FDA-required cardiac safety study and higher personnel costs, partly offset by lower clinical trial costs after the HERO and OLE trials were terminated. General and administrative expense held flat at $4.0 million in both third quarters.

Metric	Q3 2026	Q3 2025
R&D expense	$15.7M	$13.7M
G&A expense	$4.0M	$4.0M
Net loss	$19.2M	$16.3M
Net loss per share	$0.88	$0.75

For the nine months ended 30 September 2026, R&D expense reached $42.7 million against $34.6 million in the prior-year period, and G&A reached $14.6 million against $9.4 million. The nine-month net loss was $55.2 million, or $2.52 per share, compared with $40.0 million, or $2.12 per share, a year earlier. Total assets fell to $64.8 million from $117.2 million at 31 December 2025, reflecting the drawdown of short-term investments.

Analysis — what it means for healthcare and biotech markets

The hold removal is a regulatory de-risking event for a single-asset clinical company, but it does not resolve the commercial question. Aardvark still needs an FDA-endorsed development plan, a funded trial, and eventually efficacy data from a controlled study. The HERO Phase 3 trial randomized 67 of a planned 90 participants before early termination, and the company itself labels all efficacy data from it exploratory, observational and inconclusive.

Exploratory signals cut both ways. HQ-CT scores fell in both treatment arms, with numerically greater reductions for ARD-101 than placebo at Weeks 2, 4 and 8, but evaluable participants fell from 30 on ARD-101 and 31 on placebo at Week 2 to 11 and 13 at Week 12. In the open-label extension, participants who switched from placebo to ARD-101 showed an average additional 6-point HQ-CT reduction after four weeks, and OLE participants averaged an 11.8-point reduction versus their HERO baseline. The OLE had no control group.

Safety is the counter-argument investors will weigh. ARD-101 was generally well tolerated, with most adverse events mild to moderate, and treatment-emergent events reported in 52% of ARD-101 participants versus 50% on placebo. One serious cardiac adverse event occurred at 800 mg BID in a participant also taking pitolisant, a CYP2D6 substrate; the FDA concurred the event stemmed from that drug-drug interaction. Aardvark said it believes the risk can be managed by restricting or adjusting concomitant CYP2D6 substrate medications.

Positioning in clinical-stage biotech of this size tends to be specialist-driven, with outcomes tied to binary regulatory and data readouts rather than to sector flow. The report gives no institutional ownership or short-interest figures.

Outlook — what to watch next

The first-quarter 2027 FDA meeting is the nearest hard catalyst. Aardvark said it intends to provide further details on the ARD-101 development pathway after FDA feedback, and it expects to resume PWS clinical activities in 2027 subject to alignment with the agency. Until that meeting concludes, the design, size, endpoints and cost of any pivotal trial remain undisclosed.

Cash is the second variable. The company's own projection is that existing cash, cash equivalents and short-term investments carry it through 2027, but the report gives no quarterly burn guidance and no financing plans. Investors tracking the name should watch for any update to that runway statement, since a pivotal PWS program would consume capital faster than the current cardiac-study phase.

The report names no price levels, no moving averages and no analyst targets for AARD, so there are no technical thresholds to cite from it. The company also did not disclose enrollment targets, trial sites or a data-readout date for the planned open-label study.

Frequently Asked Questions

What does the FDA clinical hold lift mean for Aardvark Therapeutics shareholders?

A clinical hold stops a company from running trials under its IND. Lifting it lets Aardvark restart ARD-101 work in Prader-Willi Syndrome, but the company still needs an FDA-agreed development plan and funding. The report shows $60.3 million in cash at 30 September 2026 and a Q1 2027 FDA meeting, so the near-term value driver is regulatory clarity, not revenue.

Why did Aardvark's net loss widen in the third quarter of 2026?

The company reported a $19.2 million net loss versus $16.3 million a year earlier, driven mainly by R&D rising to $15.7 million from $13.7 million. Aardvark attributed the increase to the FDA-required cardiac safety study of ARD-101 and higher personnel costs, partially offset by lower clinical trial spending after the HERO and OLE trials ended.

What did the terminated HERO trial actually show for ARD-101?

HQ-CT hyperphagia scores fell in both arms, with numerically larger reductions for ARD-101 than placebo at Weeks 2, 4 and 8, and clinician-rated CGI-S improvement also numerically favored ARD-101 in patients with baseline HQ-CT of 13 or higher. Aardvark calls the data exploratory and inconclusive because only 67 of 90 planned participants were randomized and evaluable counts fell sharply by Week 12.

Bottom Line

Aardvark's hold removal restarts a single-asset PWS program, but the Q1 2027 FDA meeting and a $60.3 million runway now decide its path.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.